Digging into the science–and promise–of long-acting injectable PrEP
From lenacapavir offering 100% protection against HIV among cis women, to the potential for long-acting PrEP to end the HIV epidemic, Liz Highleyman offers a thorough overview of the current state of injectable PrEP.